All articles
Cancer Immunology· 2 min read

Tumour Mutational Burden: How TMB Is Measured

Tumour mutational burden (TMB) is a count of mutations within an amount of sequenced DNA. It is a computationally derived metric whose reported value depends on panel size, filtering and pipeline choices.

Quick Answer

Tumour mutational burden (TMB) is a count of mutations within an amount of sequenced DNA. It is a computationally derived metric whose reported value depends on panel size, filtering and pipeline choices.

Tumour Mutational Burden: How TMB Is Measured: mechanism and interpretation mapThree connected stages summarise the article's mechanism, measured effect and interpretation boundary.TP53 · BRCA1 · ATM1A Count With a DenominatorMechanism2Why Platforms DifferObserved consequence3Key TakeawaysInterpret in contextGene or pathway evidence → measured phenotype → assay-aware conclusion
Mechanism map: the article’s main biological stages are separated from the final interpretation so a pathway relationship is not mistaken for a clinical conclusion.

A Count With a Denominator

TMB is often expressed as mutations per megabase. Whole-exome and targeted-panel estimates are related but not identical measurements.

Why Platforms Differ

Panel breadth, variant filtering, germline handling and bioinformatics affect the estimate. Cross-platform comparison needs assay-aware calibration rather than a simple number match.

Key Takeaways

  • ·TMB is assay-dependent.
  • ·A value needs its unit, panel and method.
  • ·TMB and MSI are separate biomarkers.

Put these genes in pathway context

Frequently asked questions

What is the key idea in Tumour Mutational Burden: How TMB Is Measured?

Tumour mutational burden (TMB) is a count of mutations within an amount of sequenced DNA. It is a computationally derived metric whose reported value depends on panel size, filtering and pipeline choices.

What should be kept with the result or mechanism?

TMB is assay-dependent. A value needs its unit, panel and method. TMB and MSI are separate biomarkers.

References

  1. 1TMB harmonization project. Annals of Oncology, 2021. PubMed
  2. 2TMB as a biomarker. Nature Reviews Clinical Oncology, 2019. PubMed
  3. 3Cancer clonal evolution. Nature Reviews Genetics, 2015. PubMed

Continue Reading

Choose your next research step

Move from this explanation into a gene profile, a pathway map, or the next evidence update.

TP53 has 100+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.